Important clinical data published in Clinical Infectious Diseases demonstrated practical effectiveness of Resistance Guided Therapy for treating gonorrhoea. Led by Dr. Jeffrey Klausner, Professor of epidemiology and medicine at UCLA,...
The pandemic environment of COVID-19 has shined a spotlight on the importance of clinical diagnostics. Now, more than ever, the growth and success of SpeeDx has global reach in terms...
Important data using ResistancePlus® MG to investigate over 1500 symptomatic vaginitis patients. Mycoplasma genitalium (Mgen) infection was more prevalent in women with bacterial vaginosis (BV) (7.0% Mgen positive) compared with...
Dr. Maria Trent, a Professor of Pediatrics and Public Health at Johns Hopkins Medicine, is spearheading efforts to raise awareness and learn more about Mycoplasma genitalium, a sexually transmitted disease...
In her interview with Dr Norman Swan on ABC Radio National Health Report, Dr. Bradshaw discusses a new successful treatment pathway for Mycoplasma genitalium in a population exhibiting rising rates...
Important updates to the UK BASHH M. genitalium management guidelines are taking the issue of antimicrobial resistance (AMR) seriously. The draft guidelines have been posted for consultation and include a...
SpeeDx has significantly contributed to the success and development of the Australian MedTech industry. The CSIRO’s Medical Technologies and Pharmaceutical Roadmap, released in April, identifies Australia as being responsible for...
SpeeDx's Alison Todd frontline fighter in the war on superbugs Alison Todd co-founded SpeeDx with Elisa Mokany in 2008. The company manufactures and sells tests for detecting infectious pathogens and identifying...
The macrolide azithromycin is recommended for treatment of Mycoplasma genitalium infection; however, M. genitalium strains possessing macrolide resistance-mediating mutations (MRMMs) are increasingly being reported. Key Findings 63.6% M.genitalium-positive samples indicated macrolide...
Strategic commercial partnership in key European markets with Cepheid. SYDNEY, AUSTRALIA--(Marketwired - Jun 8, 2017) - SpeeDx Pty, Ltd., a developer of innovative molecular diagnostic solutions, today announced an agreement with...